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reduced intensity conditioning regimens (RIC) for about 60% of
the patients of MHH, as well as standard conditioning regimens
(mainly TBI + Cy or Busulfan + Cy). GvHD-prophylaxis was cyclo-
sporine A (CSA) and mycophenolate (MMF) or CSA metothrexate
(MTX), as appropriate. In addition, about 80% percent of the pa-
tients received ATG (antithymocyte globulin) prior to HSCT.
A peptide pattern of 31 peptides – either absent/decreased (15) or
present/increased (16) – was previously published (Weissinger et al.
2007), a new pattern MS_17 was developed and prospectively evalu-
ated in parallel for the last 2 years. Prospective and blinded evalua-
tion of the patients included in this analysis for early recognition
of patients at risk for aGvHD development revealed the correct clas-
sification of patients developing aGvHD about 7 days prior to the
development of clinical symptoms for aGVHD with a sensitivity
76% and specificity of about 85%. Additional data on the efficacy
of a pilot study for pre-emptive therapy driven by pattern positivity
yielded encouraging results on incidence and severity of aGvHD will
be reported. Based on these data a pre-emptive therapy multicenter
trial, administering steroids upon positivity of the proteomic pattern
has been initiated now in 10 German centers, testing the efficacy of
the pre-emptive therapy on incidence and severity of aGvHD and
a possible benefit on overall survival of the patients.44
PROTEOMIC SCREENING APPLIED TO EARLY THE DIAGNOSIS OF
CHRONIC GRAFT-VERSUS-HOST-DISEASE
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Chronic graft versus host disease (GvHD), or late acute GvHD
play a major role in morbidity, but also mortality of patients post al-
logeneic HSCT. Diagnosis chronic GvHD is based on clinical fea-
tures and biopsies, a non invasive, unbiased laboratory test does
not exist.
We established a proteomic screening test for cGvHD by using
capillary electrophoresis (CE) coupled on line to an ESI-Tof (elec-
trospray-ionization time of flight) mass spectrometer (MS). Screen-
ing urine collected from 20 patients (10 with limited cGvHD, 10
with extensive cGvHD) we established a proteomic pattern allowing
the diagnosis of cGvHD development. The resulting set of polypep-
tide markers (27 differentially excreted peptides) was tested on more
than 227 patients prospectively and blinded for the correct classifica-
tion of cGvHD samples. The majority of the patients included were
transplanted for hematological malignancies (n5 209), 6 for hema-
topoietic failure syndromes. The cGvHD proteomic pattern of 27
peptides was established by using 20 cases and 20 controls, consisting
of patients at least 100 days post-HSCT, with no GvHD in the his-
tory, no infections and without relapse at the time of sampling. Apro-
teomic pattern differentiating chronic from acute GvHD was
developed, since the initial pattern did cross react with aGvHD pa-
tients.Prospective and blinded evaluation of the patients revealed
the correct classification of patients developing cGvHD with a
sensitivity of 85% and specificity of 95%. Interestingly, urine from
patients developing GvHD post DLI did react with the cGvHD-
pattern and is predictive for GvHD developing post-DLI (about 2
weeks prior to DLI-GvHD development When the aGvHD-specific
proteomic pattern was applied to the screening of patients with DLI
in order to predict GvHD, only GvHD of the intestine reacted sig-
nificantly with the aGvHD pattern. Further evaluations of the
cGvHD patterns specific for particular organ manifestations are cur-
rently ongoing.45
GRAFT-VERSUS-LEUKEMIA ANTIGEN CML66 ELICITS COORDINATED B
AND T CELL IMMUNITY AFTER DONOR LYMPHOCYTE INFUSION
Zhang,W., Choi, J., Zeng,W., Alyea, E.P., Canning, C.M., Soiffer, R.J.,
Sasada, T., Ritz, J., Wu, C.J. Dana-Farber Cancer Institute, Boston, MA
Donor lymphocyte infusion (DLI) is a highly effective treatment
for relapsed chronic myeloid leukemia (CML) after allogeneic hema-
topoietic stem cell transplantation (HSCT), in which 70-80% pa-tients achieve curative responses. Despite its clinical efficacy, the
mechanism by which DLI achieves anti-tumor immunity remains
incompletely understood. CML66 is a CML-associated antigen
that is preferentially expressed in myeloid progenitor cells. CML66
elicited a potent antibody response in a patient with CML who
achieved complete molecular remission following CD4 + DLI in
the absence of graft-versus-host disease. Since CD4 + T cell re-
sponses often generate both antigen-specific antibody and CD8 + T
cell responses, we queried whether anti-CML66 antibodies were
associated with the development of cytolytic T cell immunity against
the same protein. CML66-reactive T cell clones were detected and
found to be directed against a naturally processed and presented
HLA-B*4403-restricted epitope (HDVDALLW). This T cell epi-
tope (at residues 459-467) is positioned in a different region of the
protein compared to the B cell epitope (at residues 198-217: GFYV-
SLEWVTISKKNQDNK). Neither antibody nor T cell responses to
CML66 were detectable in peripheral blood prior to DLI, by ELISA
or ELISpot assays, respectively. However, starting as early as one
month after DLI, CD8 + T cells and then high-titer plasma antibody
to CML66 were readily detected in peripheral blood, in close tempo-
ral correlation with disease remission. Examination of marrow by
ELISpot 1 month after DLI revealed a 10 fold increased frequency
of CML66-reactive CD8 + T cells compared to peripheral blood.
The CML66-reactive T cell clone could be also detected at low levels
in vivo in patient marrow prior to DLI by ELISpot and nested PCR,
in association with progressive leukemic relapse, but not in peripheral
blood pre-DLI, nor in peripheral blood of the stem cell donor. These
results suggest that marrow is a reservoir of donor T cells primed
against patient leukemia following HSCT. Infusion of CD4+ donor
T cells appears to result in the rapid expansion of pre-existing mar-
row-resident leukemia-specific CD8 + T cells, followed by a cascade
of antigen-specific immune responses detectable in the periphery.
Our detailed analysis of this single antigen demonstrates that both
B and T cell immunity contribute to effective tumor immunity that
is directed at least in part to nonpolymorphic overexpressed leukemia
antigens.46
IN CML PATIENTS, RESIDUAL DISEASE IN PRIMITIVE STEM/PROGENITOR
CELLS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION IS
HIGHER THAN AFTER TREATMENT WITH TYROSINE KINASE INHIBITORS
ALONE, BUT IS STILL AMENABLE TO GVL EFFECTS
Yong, A.S.M., Keyvanfar, K., Eniafe, R., Savani, B.N., Rezvani, K.,
Shenoy, A., Koklanaris, E.K., Musse, L., Donohue, T., Le, Q.,
Goldman, J.M., Barrett, A.J. National Heart, Lung and Blood Institute,
National Institutes of Health, Bethesda, MD
Although tyrosine kinase inhibitors (TKI) have replaced allogeneic
stem cell transplantation (SCT) as first-line therapy for chronic my-
eloid leukemia (CML), TKIs do not eradicate all CML cells. Simi-
larly, although SCT cures CML patients, minimal residual disease
(MRD) not fulfilling criteria for molecular relapse is also found
post-SCT. We compared the level of BCR-ABL transcripts in primi-
tive hematopoietic cells from patients who were treated with T-
depleted SCT with scheduled T-cell addback from D + 45 to
D + 100 post-SCT (n5 38) with levels in those taking TKIs
(n5 5). CD34+ cells were isolated from post-SCT leukaphereses at
D + 120 (n5 13), peripheral blood (PB) from D + 60 – 66 months
(n5 19), bone marrow aspirates from patients on long-term follow-
up (4-12 years) (n5 17), or 15 – 18 months post-TKI treatment alone
(n5 5); serial post-SCT samples were available in 12 patients. Hema-
topoietic stem cells (HSC, CD34 + CD38-Lin-CD90+), common
myeloid progenitors (CMP, CD34 + CD38 + Lin- IL3Ra + C-
D45RA-) and granulocyte-macrophage progenitors (GMP,
CD34 + CD38 + Lin- IL3Ra + CD45RA+) were flow-sorted, and
BCR-ABL expression measured using quantitative PCR with the sen-
sitivity to detect one BCR-ABL-positive cell in 106 normal cells. Of
twenty patients with PB MRD-negativity (n5 19 post-SCT, n5 1
post-TKI), an 11-year post-SCT patient had detectable BCR-ABL
transcripts in CMPs, and subsequently fulfilled criteria for molecular
relapse. Among PB MRD-positive patients, 3/19 (16%) post-SCT
and 2/3 (67%) post-TKI did not have detectable BCR-ABL tran-
scripts in HSC, CMP or GMP populations. In 16/19 (84%) PB
MRD-positive post-SCT patients BCR-ABL transcripts were de-
tected in at least one CD34+ subpopulation, with the highest levels
S172 Oral Presentationsin HSCs and CMPs. A rise in BCR-ABL levels in GMP populations
signified impending relapse. Post-SCT patients harbored more resid-
ual CML cells in CD34+ subpopulations than TKI-treated patients.
Our findings suggest that in patients with persistent MRD-positivity
post-SCT, the graft-versus-leukemia (GVL) effect may eliminate
mature leukemic CD34+ subpopulations in vivo more readily. Prim-
itive leukemic HSCs and CMPs, although persistent, are presumably
constrained by GVL in patients who do not fulfill criteria for relapse.
Conversely, TKI reduces the number of BCR-ABL-positive GMPs
and CMPs more efficiently. Our data support adjuvant TKI-treat-
ment for CML relapse post-SCT, and concurrent vaccination strate-
gies which can target surface proteins on HSCs to eradicate CML.HEMATOPOIESIS/MESENCHYMAL CELLS47
TIE2 + BONE MARROW ENDOTHELIAL CELLS REGULATE HEMATOPOI-
ETIC RECONSTITUTION IN VIVO
Doan, P.L.1, Russell, J.L.1,Meadows, S.K.1, Himburg, H.A.1, Daher, P.1,
Chao, N.J.1, Kirsch, D.2, Chute, J.P.1 1Duke University Medical Center,
Durham, NC; 2Duke University Medical Center, Durham, NC
Radiation and chemotherapy cause myelosuppression in patients
via damage to bone marrow (BM) hematopoietic stem/progenitor
cells (HSCs). HSCs reside adjacent to BM sinusoidal vessels but
the function of BM endothelial cells (BM ECs) in regulating HSC
fate in vivo remains less well understood. We hypothesized that
BM ECs are critical in regulating BM hematopoietic reconstitution
following radiation stress. To test this hypothesis, we used Cre-
LoxP recombination to create targeted deletion of the pro-apoptotic
genes, Bak and Bax, in Tie2 + BM ECs (Tie2Cre;Bak-/-;BaxFl/-
mice) and measured hematopoietic response to total body irradiation
(TBI). Tie2Cre;Bak-/-;BaxFl/- mice were compared with Tie2Cre;
Bak-/-; BaxFl/+ mice which have constitutive Bak deletion but retain
Bax in Tie2 + BM ECs. After exposure to 100 cGy TBI, Tie2Cre;
Bak-/-;BaxFl/- mice displayed a 2-fold increase in total viable
BM cells (p5 0.04), 4-fold increase in BM ckit+sca+lineage- (KSL)
progenitor cells (p\0.0001), 3-fold increase in colony-forming
unit-spleen day 12 content (p5 0.0003) and a 2-fold increase in 12-
week competitive repopulating units (CRUs) (p5 0.002) compared
to Tie2Cre;Bak-/-;BaxFl/+ mice. Comparable radioprotection
was observed after 300 cGy TBI. Since Tie2 is expressed by BM
ECs and a subset of BM HSCs, we wanted to determine whether
the radioprotection we observed in Tie2Cre;Bak-/-;BaxFl/- mice
was caused autonomously by protection of Tie2 + BM ECs or
Tie2 + HSCs. We transplanted 4  106 BM cells from Tie2Cre;
Bak-/-;BaxFl/- mice into lethally irradiated (950 cGy) wild type
B6.SJL mice such that the recipient mice were chimeric for Bak and
Bax deletions only in hematopoietic cells while retaining a wild
type BM microenvironment, verified by qRTPCR. At 16 weeks
post-transplant, the chimeric recipient mice were then exposed to
100 and 300 cGy TBI and we compared the hematopoietic response
of these mice to that of Tie2Cre;Bak-/-;BaxFl/- mice. After 100 cGy
TBI, the hematopoietic response of the chimeric mice revealed a sig-
nificant reduction in total viable BM cells (1.3-fold), BM KSL cells
(7.4-fold) and 12-wk CRU weeks (1.6-fold, p5 0.008) compared to
100 cGy-irradiated Tie2creBak-/-;BaxFl/- mice. These results
demonstrate that Tie2 + BM ECs positively regulate hematopoietic
reconstitution following injury and indicate that BM ECs are a novel
mechanistic target for therapies to augment hematopoietic recovery
in patients undergoing radiation and/or chemotherapy.HISTOCOMPATIBILITY/ALTERNATIVE STEM
CELL SOURCES
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PATIENT ETHNICITY MARKEDLY AFFECTS THE PROBABILITY OF FIND-
ING AN HLA-A, -B, -C, AND DRB1 ALLELE MATCHED UNRELATED DONOR
FOR HEMOPOIETIC CELL TRANSPLANTATION
Anasetti, C.1, Hillgruber, R.1, Nye, V.1, Ayala, E.1, Kharfan-
Dabaja, M.1, Fernandez, H.F.1, Field, T.1, Ochoa, J.L.1, Perez, L.E.1,Tomblyn, M.1, Benson, K.2, Davis, J.3, Dodson, K.3, Confer, D.3 1Moffitt
Cancer Center, Tampa, FL; 2Moffitt Cancer Center, Tampa, FL;
3National Marrow Donor Program, Minneapolis, MN
The adult unrelated volunteer registries include more then 14 mil-
lion donors worldwide; however, the required precision of patient
and donor matching for high resolution HLA determinants, and
the ethnic variation of the patient population put a yet unknown con-
straint to the probability of finding a suitable donor. We evaluated
the results of unrelated searches for 398 consecutive patients.
Patients and donors were typed by HLA sequencing. Searches
were assisted by NMDP histocompatibility specialists for patients
to identify an HLA-A, B, C, DRB1 match (8/8) or a partial match
(7/8). HLA-DQB1 was considered in the search, but was not evalu-
ated in this analysis. For the purpose of this study, the search was
completed when confirmatory typing on a freshly drawn donor sam-
ple identified the first suitable donor. Such a donor was found for 336
(85%) patients after a median of 20 [95% C.I. 11-59] days: this was
an 8/8 match for 209 (53%) patients and a 7/8 for 127 (32%) patients,
with no difference in search duration observed by matching grade.
With a 7/8, the mismatch was at -A (35%), -B (26%), -C (28%), or
-DRB1 (11%). The probability of finding a donor was not affected
by patient age or diagnosis, but was affected by the patient ethnicity.
An 8/8 match was found for 181/293 (62%) Caucasians, 22/65 (34%)
Hispanics, and 6/40 (15%) African-Americans, and a 7/8 match was
found for 80 (27%) Caucasians, 28 (43%) Hispanics and 19 (48%)
African-Americans (p\0.0001). Therefore, only 11% of Caucasians
had no suitable donor compared to 23% of Hispanics and 37% of
African Americans.
Consistent with overall NMDP data, among those with a suitable
match, 161/336 (48%) patients reached transplantation after a
median of 101 [95% C.I.; 56-258] days from the search inception.
The interval from finding the first donor to transplant was a median
of 81 [95% C.I.: 45-199] days, about 4-fold longer than the search
itself. Reaching transplant was affected by the match grade, 107/
209 (51%) for 8/8, 54/127 (43%) for 7/8, and 3/62 (5%) for those
without a match (p\0.0001). The low probability of reaching trans-
plant despite a suitable donor is alarming: 40% deteriorated or died,
17% received other treatment modalities, 14% declined or failed to
make a decision, 14% waited for a better match, 16% other reasons.
A suitably matched unrelated donor is available for the large majority
of the patients, however, Hispanic or African-American ethnicity
represents a barrier to find a suitable donor.49
CAN HISTOCHECK ALGORITHM PREDICT HIGH-RISK HLA ALLELE MIS-
MATCH COMBINATIONS RESPONSIBLE FOR SEVERE ACUTE GRAFT-VER-
SUS-HOST DISEASE?
Askar, M.1, Sobecks, R.2, Makishima, H.3, Maciejewski, J.2,3 1Allogen
Laboratories; 2Taussig Cancer Center; 3Cleveland Clinic, OH
HLA polymorphism remains a major hurdle for hematopoietic
stem cell transplantation (HSCT). In 2004 Elsner et al (BMT) pro-
posed the ‘‘HistoCheck’’ web-based tool to estimate the allogeneic
potential between HLA-mismatched stem cell recipient/donor pairs
expressed as a matching score (dissimilarity score, DSS). DSS is
based on the structural data of HLA molecules and the functional
similarity of amino acids. A high DSS score represents high dissim-
ilarity between MHC molecules.
Objective: We sought to investigate the potential of DSS to predict
high-risk HLA allele mismatch combinations responsible for severe
acute graft-versus-host disease (aGvHD grades III and IV) from data
recently published by Kawase et al, Blood, 2007 by comparing DSS
in low and high risk combinations.
Method: DSS were calculated for 110 HLA allele mismatch combi-
nations observed in 3830 donor/recipient pairs using the Histo-
Check tool available on the Web (WWW.histocheck.org). We
compared ranges and means of DSS among high risk versus low
risk allele combinations.
Results: An example of a higher risk combination is Cw*0303 (do-
nor) – 1502 (patient) that was observed in 25 pairs with HR of
3.22 (p\0.001). A lower risk combination containing the same re-
cipient allele but a different donor option is Cw*0801 – 1502 (ob-
served in 36 pairs) with HR of 1.59 (p5 0.19). DSS for these 2
